NATIONAL BUREAU OF ECONOMIC RESEARCH
NATIONAL BUREAU OF ECONOMIC RESEARCH
loading...

Economic Dimensions of Personalized and Precision Medicine

Ernst R. Berndt, Dana P. Goldman, and John W. Rowe, editor

Conference held September 13-14, 2017
Published in April 2019 by University of Chicago Press
© 2019 by the National Bureau of Economic Research

NBER Program(s):HE, HC

More information on purchasing this book
349 pages
ISBN: 978-0-226-61106-8

Table of Contents

Introduction: Ernst R. Berndt, Dana P. Goldman, John W. Rowe (p. 1 - 7) (bibliographic info)
1. The Economic Value and Pricing of Personalized Medicine: Tomas J. Philipson (p. 9 - 19) (bibliographic info)
2. Therapeutic Translation of Genomic Science: Opportunities and Limitations of GWAS: Manuel Hermosilla, Jorge Lemus (p. 21 - 52) (bibliographic info) (Working Paper version)
3. The Value of Pharmacogenomic Information: John A. Graves, Zilu Zhou, Shawn Garbett, Josh F. Peterson (p. 53 - 86) (bibliographic info) (Working Paper version)
4. The Information Pharms Race and Competitive Dynamics of Precision Medicine: Insights from Game Theory: Ernst R. Berndt, Mark R. Trusheim (p. 87 - 114) (bibliographic info) (Working Paper version)
5. Characterizing the Drug Development Pipeline for Precision Medicines: Amitabh Chandra, Craig Garthwaite, Ariel Dora Stern (p. 115 - 157) (bibliographic info) (Working Paper version)
6. Cost Sharing in Insurance Coverage for Precision Medicine: Mark V. Pauly (p. 159 - 184) (bibliographic info) (Working Paper version)
7. Measuring the Potential Health Impact of Personalized Medicine: Evidence from Multiple Sclerosis Treatments: Kristopher J. Hult (p. 185 - 216) (bibliographic info) (Working Paper version)
8. Physicians’ Financial Incentives to Personalize Medicine: David H. Howard, Jason Hockenberry, Guy David (p. 217 - 235) (bibliographic info) (Working Paper version)
9. Economic Dimensions of Personalized and Precision Medicine in Asia: Evidence from Breast Cancer Treatment in Taiwan: Jui-fen Rachel Lu, Karen Eggleston, Joseph Tung-Chieh Chang (p. 237 - 272) (bibliographic info)
10. The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event: Evidence from Geisinger: Rebecca A. Pulk, Jove Graham, Frank R. Lichtenberg, Daniel Maeng, Marc S. Williams, Eric Wright (p. 273 - 304) (bibliographic info)
11. Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies: Philippe Gorry, Diego Useche (p. 305 - 334) (bibliographic info)
 
Publications
Activities
Meetings
NBER Videos
Themes
Data
People
About

National Bureau of Economic Research, 1050 Massachusetts Ave., Cambridge, MA 02138; 617-868-3900; email: info@nber.org

Contact Us